Aviragen Therapeutics Inc Share Price Nasdaq
Equities
US0906941002
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
14/03 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
14/03 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 14.73M 1.23B | Sales 2025 * | 23.1M 1.93B | Capitalization | 125M 10.41B |
---|---|---|---|---|---|
Net income 2024 * | -77M -6.43B | Net income 2025 * | -80M -6.68B | EV / Sales 2024 * | 8.46 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.4 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-1.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Aviragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 01/04/01 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 19/22/19 |
Michael Finney
CHM | Chairman | 65 | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 25/19/25 |
Elaine Heron
BRD | Director/Board Member | 76 | 25/22/25 |
Michael Finney
CHM | Chairman | 65 | 01/07/01 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |